OP95
Anti-BRCA2 (Ab-1) Mouse mAb (2B)
liquid, clone 2B, Calbiochem®
Sinónimos:
Anti-Breast Cancer Susceptibility Protein
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
NACRES:
NA.43
UNSPSC Code:
12352203
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Anti-BRCA2 (Ab-1) Mouse mAb (2B), liquid, clone 2B, Calbiochem®
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
2B, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
dilution
(Immunoblotting (2 µg/mL)
Immunoprecipitation (2 µg))
isotype
IgG2b
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... BRCA2(675)
Analysis Note
Positive Control
MCF7 cells
MCF7 cells
Application
Immunoblotting (2 µg/ml)
Immunoprecipitation (2 µg)
Immunoprecipitation (2 µg)
Disclaimer
Toxicity: Standard Handling (A)
General description
Anti-BRCA2 (Ab-1), mouse monoclonal, clone 2B, recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. It is validated for Western blotting and immunoprecipitation.
Purified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with myeloma cells. Recognizes the ~460 kDa BRCA2 protein.
Recognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Immunogen
Human
a recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
Legal Information
Sold under license of U.S. Patents 5,837,492 and 6,124,104.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Andres, J.L., et al. 1998. Oncogene16, 2229.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
Chen, J., et al. 1998. Mol. Cell2, 317.
Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13869.
Connor, F., et al. 1997. Nat. Genet.17, 423.
Sharan, S.K., et al. 1997. Nature386, 804.
Ludwig, T., et al. 1997. Genes Dev.11, 1226.
Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA94, 6927.
Rajan, J.V., et al. 1997. Dev. Biol.184, 385.
Suzuki, A., et al. 1997. Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997. J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol.23, 1.
Goggins, M., et al. 1996. Cancer Res.56, 5360.
Stratton, M.R. 1996. Hum. Mol. Genet.5, 1515.
Tavtigian, S.V., et al. 1996. Nat. Genet.12, 333.
Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock. 1996. Oncogene13, 1639.
Vaughn, J.P., et al. 1996. Cancer Res.56, 4590.
Wooster, R., et al. 1995. Nature378, 789.
The CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In PBS.
Preparation Note
Following initial thaw, aliquot and freeze (-20°C).
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Nathalie van den Tempel et al.
Cancers, 11(1) (2019-01-18)
The DNA damage response (DDR) is a designation for a number of pathways that protects our DNA from various damaging agents. In normal cells, the DDR is extremely important for maintaining genome integrity, but in cancer cells these mechanisms counteract
Nathalie van den Tempel et al.
PloS one, 13(12), e0209101-e0209101 (2018-12-15)
Bladder cancer (urothelial carcinoma) is a common malignancy characterized by high recurrence rates and intense clinical follow-up, indicating the necessity for more effective therapies. Current treatment regimens include intra-vesical administration of mitomycin C (MMC) for non-muscle invasive disease and systemic
null
Javier Garzón et al.
Cell reports, 27(9), 2558-2566 (2019-05-30)
RIF1 is a multifunctional protein implicated in controlling DNA replication and repair. Here, we show that human RIF1 protects nascent DNA from over-degradation at stalled replication forks. The major nuclease resecting nascent DNA in the absence of RIF1 is DNA2
Reihaneh Zarrizi et al.
The Journal of clinical investigation, 130(8), 4069-4080 (2020-05-08)
Haploinsufficiency of factors governing genome stability underlies hereditary breast and ovarian cancer. One significant pathway that is disabled as a result is homologous recombination repair (HRR). With the aim of identifying new candidate genes, we examined early-onset breast cancer patients
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico